From Glioblastoma Treatments
Jump to navigationJump to search
|
|
| (One intermediate revision by the same user not shown) |
| Line 1: |
Line 1: |
| {{TreatmentInfo
| | |
| |drug_name=Cimetidine (Tagamet)
| |
| |FDA_approval=Yes (for stomach conditions, not specifically approved for brain cancer yet)
| |
| |used_for=Experimental for glioblastoma; approved for stomach acid reduction; noted use in colon cancer
| |
| |mechanism_of_action=Decreases cell migration by affecting genes controlling cellular adhesion
| |
| |clinical_trial_year=Recent (specific year not mentioned)
| |
| |number_of_patients=N/A (mouse study)
| |
| |median_survival=Substantially longer survival in mice with temozolomide + cimetidine
| |
| |category=Repurposed Drugs
| |
| |additional_notes=Potential to interact with numerous other drugs affecting their metabolism in the liver.
| |
| |toxicity_level=
| |
| |toxicity_level=2
| |
| }}
| |
Latest revision as of 09:29, 27 March 2024
